Last reviewed · How we verify
NCT06011694
The Jinling Cohort
trial testing MERCURY test, health questionnaires and annual routine physical exams in Cancer in 15,000 participants. Currently enrolling.
15 May 2027
Quick facts
| Lead sponsor | Nanjing Shihejiyin Technology, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 15,000 |
| Start date | 15 June 2022 |
| Primary completion | 15 May 2027 |
| Estimated completion | 15 May 2027 |
| Sites | 2 locations across China |
Drugs / interventions tested
- MERCURY test, health questionnaires and annual routine physical exams
Conditions studied
- Cancer — all drugs for Cancer →
- Multi Cancer Early Screening — all drugs for Multi Cancer Early Screening →
- Liquid Biopsy — all drugs for Liquid Biopsy →
Sponsor
Nanjing Shihejiyin Technology, Inc. — full company profile →
Who can join
Adults 45 to 75, any sex, with Cancer or Multi Cancer Early Screening. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
Imai M, Nakamura Y, Yoshino T. · · 2025 · cited 15× · PMID 39799530 · DOI 10.1007/s10147-025-02694-5 -
Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening.
Galeș LN, Păun MA, Anghel RM, Trifănescu OG. · · 2024 · cited 9× · PMID 38539525 · DOI 10.3390/cancers16061191 -
Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation.
Xu Y, Zhu S, Xia C, Yu H, et al · · 2025 · cited 2× · PMID 40670203 · DOI 10.1016/j.scib.2025.06.030 -
Multicancer Early Detection Tests: A State-of-the-Art Review for Otolaryngologists.
Kennedy E, Durm G, Farlow JL. · · 2024 · cited 2× · PMID 39463807 · DOI 10.1002/oto2.70040 -
Lung cancer in never-smoking females: epidemiology, risk factors and screening
Ding Y, Tao H, Zhu C, Li H, et al ·
Verify or expand the search:
- PubMed search for NCT06011694
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06011694 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing Shihejiyin Technology, Inc.
- Last refreshed: 25 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06011694.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing